文献速递药物不良反应与药物警戒

新型直接肾素抑制剂SPH3127片治疗轻中度原发性高血压的III期随机试验

Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial.
PubMed 文献 · Drugs · 2026-05-21

这项多中心、随机、双盲、平行III期试验分两阶段进行,评估SPH3127片与缬沙坦胶囊治疗轻中度原发性高血压的疗效与安全性;第二阶段828例患者随机接受SPH3127 100 mg(N=413)或缬沙坦80 mg(N=415)每日一次治疗12周,主要终点坐位舒张压变化组间差异为-0.35 mmHg(95%CI:-1.48,0.78,p=0.005),结论认为SPH3127 100 mg每日一次有效且安全。

要点

  • SPH3127 100 mg每日一次降压疗效与缬沙坦80 mg每日一次相当。
  • SPH3127组药物不良反应发生率8.3%,低于缬沙坦组的10.0%。
  • 严重不良事件均与研究药物无关,缬沙坦组1例死亡因心肌梗死。

核心结论

  • 口服SPH3127片100 mg每日一次对成人轻中度原发性高血压有效且安全。

研究设计与样本

  • 多中心、随机、双盲、平行III期试验,分两阶段设计。
  • 第一阶段189例入组、129例随机,接受SPH3127 50 mg、100 mg、200 mg或缬沙坦80 mg每日一次治疗12周。
  • 第二阶段筛选1260例、828例随机接受SPH3127 100 mg(N=413)或缬沙坦80 mg(N=415)每日一次治疗12周。
  • 主要终点为第12周平均坐位舒张压(msDBP)较基线的变化。

主要发现

  • 第一阶段SPH3127 100 mg组血浆肾素活性抑制效应达83%,第12周msDBP较基线降幅最大为-8.17±5.90 mmHg。
  • 第二阶段SPH3127组第12周msDBP变化为5.97(0.41)mmHg,缬沙坦组为6.32(0.41)mmHg,组间差异-0.35 mmHg(95%CI:-1.48,0.78,p=0.005)。
  • 假设策略分析显示SPH3127组msDBP变化5.95(0.41)mmHg,缬沙坦组6.31(0.42)mmHg,组间差异-0.36 mmHg(95%CI:-1.51,0.78,p=0.006)。
  • 12周治疗期间,SPH3127组250例(61.1%)和缬沙坦组231例(56.2%)报告治疗中出现的不良事件(TEAE)。
  • 药物不良反应(ADR)在SPH3127组报告34例(8.3%),缬沙坦组41例(10.0%)。

关键数值与推荐

  • SPH3127 100 mg每日一次为第二阶段选定剂量。
  • 主要终点组间差异-0.35 mmHg(95%CI:-1.48,0.78,p=0.005)。
  • 敏感性分析组间差异-0.36 mmHg(95%CI:-1.51,0.78,p=0.006)。
  • TEAE发生率SPH3127组61.1% vs 缬沙坦组56.2%。
  • ADR发生率SPH3127组8.3% vs 缬沙坦组10.0%。

临床怎么用

  • SPH3127 100 mg每日一次可作为轻中度原发性高血压的降压选择之一。
  • 用药期间关注不良事件,尤其ADR发生率约8.3%。
  • 严重不良事件与研究药物无关,但需常规监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of sitokiren (SPH3127) tablet in patients with mild-to-moderate essential hypertension in comparison to valsartan capsule. METHODS: This multicentre, randomised, double-blind, parallel Phase III trial was designed in 2 stages. In the 1st stage, eligible patients were randomised to receive 50 mg, 100 mg or 200 mg of SPH3127 tablet or 80 mg of valsartan capsule once daily (QD) for 12 consecutive weeks. In the 2nd stage, eligible patients were randomised to receive assigned dose of SPH3127 tablet based on the results from the 1st stage or valsartan 80 mg QD for 12 consecutive weeks. Primary outcome was the change from baseline in mean sitting diastolic blood pressure (msDBP) at Week 12. Safety outcome measures included any adverse events. Exploratory outcomes included plasma concentration of SPH3127, as well as the assessment of the correlation between SPH3127 exposure with the level of renin inhibition, clinical efficacy and occurrence of adverse events. RESULTS: The 1st stage enrolled 189 patients, of which 129 eligible patients were randomised. High plasma renin activity (PRA) inhibitory effect (83%) and the biggest reduction of msDBP at Week 12 from baseline (- 8.17 ± 5.90 mmHg) was detected in SPH3127 group at the dosage of 100 mg, which was determined for the subsequent stage 2 of this trial. The 2nd stage screened 1260 patients, of which 828 eligible patients were randomised to receive SPH3127 tablet 100 mg (N = 413) and valsartan capsule 80 mg (N = 415), QD. Main analysis based on the treatment policy strategy indicated 5.97 (0.41) mmHg [least-square mean (LSM) and standard error (SE)] of the msDBP changes at Week 12 from baseline in the SPH3127 and 6.32 (0.41) in valsartan groups, with inter-group difference of - 0.35 mmHg (95% CI: - 1.48, 0.78, p = 0.005). Main analysis based on hypothetical strategy showed 5.95 (0.41) mmHg of the msDBP changes at Week 12 from baseline in the SPH3127 and 6.31 (0.42) mmHg in valsartan groups, with inter-group difference of - 0.36 mmHg (95% CI: - 1.51, 0.78, p = 0.006). During the 12-week treatment period, 250 (61.1%) patients in SPH3127 group and 231 (56.2%) patients in valsartan group reported treatment emergent adverse events (TEAEs). Adverse drug reaction (ADR) was reported by 34 (8.3%) and 41 (10.0%) patients in SPH3127 and valsartan group, respectively. The serious adverse events (SAEs) reported by 10 patients were considered not related to the investigational drugs. Death was reported in 1 patient in the valsartan group due to myocardial infarction, which was considered not related to the study drug. CONCLUSIONS: Oral SPH3127 tablet 100 mg QD is effective and safe for adult patients with mild-to-moderate essential hypertension. TRIAL REGISTRATION: Clinicaltrials.gov Identifier number NCT05359068.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Lv Q, Ma C, Wang F, et al. Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial. Drugs. 2026. PMID: 42165988. doi:10.1007/s40265-026-02315-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。